This is a very special time for clinical and translational research on glioblastoma.
Clinical trials testing anti-angiogenic drugs are providing exciting results, showing the potential for significant improvement of survival and quality of life in patients affected by this dreadful disease. These trials are part of a long path of translational research mostly pointed at the role of the vascular endothelial growth factor in glioblastoma biology and at the potential of its inhibition for patients with primary and recurrent glioblastoma.
In term of translational research genomic investigations of The Cancer Genome Atlas project start providing relevant results for patient stratification and, possibly, novel targeted treatments. Cancer immunology is also gaining momentum and the potential of its clinical impact is increasing.
Glioblastoma 2013 intends to provide a forum for experts involved in clinical or translational research on glioblastoma, fostering an open and fruitful scientific discussion.